This content was produced with the help of AI and reviewed by STN editors before being published.
Transcranial Magnetic Stimulation (TMS) has been FDA-approved for the treatment of major depressive disorder since 2008. Since then, it has received additional FDA clearances for OCD (2018) and PTSD (2020), and is used off-label for a growing number of other conditions. With that history comes a substantial body of clinical research, enough to draw meaningful conclusions about who benefits, how much, and what the limitations are.
This article summarizes the evidence honestly. TMS is genuinely effective for the right patients. It is also not a universal cure, and understanding realistic expectations is important.
The landmark clinical trial that led to FDA approval, a multicenter, randomized, sham-controlled study published in Biological Psychiatry, found that TMS produced significantly greater response rates than sham treatment in patients with treatment-resistant major depressive disorder. The active TMS group showed approximately 24% remission at the end of the acute treatment phase.
Follow-up naturalistic studies examining real-world outcomes have generally shown higher response and remission rates than the controlled trial, likely because clinical populations are selected more carefully for candidacy than research populations are. A large naturalistic study (the NeuroStar TMS Therapy Patient Registry) found response rates of approximately 58% and remission rates of approximately 37% in routine clinical practice.
More recent studies using newer protocols, particularly Theta Burst Stimulation (TBS), show comparable efficacy to standard rTMS with significantly shorter session times (3 minutes vs. 37 minutes for intermittent TBS in the SAINT protocol), making treatment more accessible.
The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol has generated significant interest. In a 2021 randomized controlled trial, an intensive, personalized TMS protocol (50 sessions over 5 days, targeting the DLPFC based on individual fMRI connectivity) produced remission in 78.6% of participants with severe treatment-resistant depression, compared to 13.3% in the sham group.
This represents a dramatic advance over standard TMS and suggests that protocol personalization and intensification may significantly improve outcomes. While SAINT is not yet widely available in clinical practice, it signals the direction of TMS development.
The FDA clearance for deep TMS in OCD (2018) was based on a multicenter, randomized controlled trial that found deep TMS produced significantly greater reductions in OCD symptom severity than sham treatment. The response rate (>30% reduction in Y-BOCS score) was 38.1% in the active group vs. 11.1% in the sham group.
Critically, the protocol involved a 90-second symptom provocation immediately before each session, combining elements of Exposure and Response Prevention (ERP) with TMS stimulation. This suggests that TMS in OCD works best when integrated with behavioral principles.
FDA clearance for PTSD was granted in 2020 based on clinical evidence showing that right DLPFC TMS reduced PTSD symptom severity in patients who had not responded adequately to first-line treatments. TMS for PTSD is often combined with trauma-focused therapy, with early evidence suggesting this combination may outperform either treatment alone.
It is equally important to understand the limitations of TMS:
Research and clinical experience suggest that the following factors are associated with better TMS outcomes:
At Segal Telepsychiatry Network, our TMS team conducts comprehensive evaluations to determine candidacy and select the most appropriate protocol for each patient, including qEEG brain mapping to individualize targeting. Learn more about TMS therapy or schedule a consultation.
Segal Telepsychiatry Network serves patients in California, Florida, and New York. No referral needed. We typically schedule within days.
Get Started Today
